As of May 2025, there is no publicly accessible information indicating that Renaissance Technologies has identified Gilead Sciences as a top stock pick. The hedge fund, founded by Jim Simons, who passed away in May 2024, is known for its cutting-edge quantitative investing strategies.
Gilead Sciences is a leading biopharmaceutical firm known for developing antiviral drugs targeting conditions like HIV/AIDS, hepatitis, and COVID-19. Despite Renaissance Technologies' historical investments across various sectors, including healthcare, specifics on their current investments, such as in Gilead, remain undisclosed.
Investment details for Renaissance Technologies are usually kept private, and without official announcements or regulatory filings, it's difficult to ascertain their present stake in companies like Gilead Sciences. For the latest insights into their investment activities, checking their formal communications or SEC filings would be recommended.